SciELO - Scientific Electronic Library Online

 
vol.38 issue1Serotonin syndrome secondary to the use of paroxetine in a patient under systematic hemodiálisis regime author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Cubana de Medicina Militar

Print version ISSN 0138-6557On-line version ISSN 1561-3046

Abstract

MULET PEREZ, Agustín et al. Acute viral hepatitis C: treatment with high dose of human recombinant alpha 2b interpheron (Heberon alfa R). Rev Cub Med Mil [online]. 2009, vol.38, n.1. ISSN 0138-6557.

INTRODUCTION: For the treatment of acute viral hepatitis C, a number of therapeutic regimes with Interferon has been put forward. This paper presented our own experience in the application of a therapy different from the Standard treatment recommended in Cuba, which consisted of the parenteral administration of 3 million doses of recombinant Interferon Alpha 2b three times a week for 6 months. METHODS: The medical records of two patients, who were diagnosed with acute viral hepatitis C on the basis of clinical and epidemiological data, humoral alterations and positive viral markers, were reviewed, using histological diagnosis in one of them. They were administered 5 million Heberon Alpha R subcutaneously for 4 weeks and then additional 5 millions using the same way of administration three times a week to complete 6 months of treatment. RESULTS: Two months after finishing the treatment, the patients remained asymptomatic, gluthamic-piruvic transaminase scores were normal and Virus C RNA proved to be negative after evolving PCR. CONCLUSIONS: The therapy used in these patients proved to be effective, so it is recommended to treat acute viral hepatitis C.

Keywords : acute hepatitis C; treatment; recombinant interferon alpha..

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License